Calypso Technology, Inc., the global capital markets platform provider, has announced the appointment of David Kelly as Director of Financial Engineering.
Mr. Kelly has nearly 20 years of experience in finance as a trader, quant and technologist and will be responsible for the Financial Engineering team at Calypso.
Mr. Kelly's hire comes as part of an ongoing initiative to expand Calypso's expert team of financial engineers and to seek out highly talented, seasoned industry veterans. Mr. Kelly has previously held senior positions at some of the largest financial institutions and was most recently the Director of Credit Product Development at Quantifi. As a member of Quantifi's senior management team, Mr. Kelly oversaw quantitative and technical staff in providing pricing and risk solutions to global banks, asset managers, hedge funds and insurance companies.
Prior to Quantifi, Mr. Kelly was a senior trader on Citigroup's CVA desk and was formerly Head of the Global Analytics group at JPMorgan Chase, where he also designed and developed the first CVA pricing and risk management system for the Credit Portfolio Trading desk. Mr. Kelly's buy-side experience includes serving as CRO for a prominent hedge fund, where he defined and implemented risk management processes and systems. As Director of Financial Engineering at Calypso, Mr. Kelly will be reporting to Tej Sidhu, Senior Vice President of Engineering.
Mr. Kelly comments, "I'm thrilled to be joining Calypso, a firm that has repeatedly made the right calls in pursuing new market opportunities, such as central clearing and the need for consolidated cross-asset risk and liquidity management solutions. This is a time of rapid growth and expansion for the firm and I look forward to lending my experience and insights to the Financial Engineering team as we look to further enhance our sophisticated derivatives pricing analytics, including CVA."
Kishore Bopardikar, President and CEO of Calypso, notes, "David brings tremendous experience and expertise to our Financial Engineering team. His appointment is a part of our commitment to innovation. We are always lookiing to break new ground in the OTC derivatives industry and David has a history of bringing new and valuable developments to the industry. We are excited to have him on board.".